AMPLIFY trial - Target number of participants achieved
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Clarity Pharmaceuticals Ltd. has announced that its Phase III AMPLIFY trial has successfully achieved its target number of participants, following strong demand for study participation in the US and Australia. The trial aims to evaluate the diagnostic ability of a specific PET imaging agent in detecting prostate cancer recurrence in men with elevated PSA levels. Dr. Alan Taylor, Executive Chairperson, highlighted the rapid recruitment pace and the unmet need for effective prostate cancer diagnostics as key factors in the trial's success. The results from this pivotal trial are intended to support an application for FDA approval of the imaging agent as a new diagnostic tool for prostate cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Half Yearly Report and Accounts
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- SECuRE trial update
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- Co-PSMA abstract released
Later from Clarity Pharmaceuticals
- Registrational Phase III AMPLIFY trial: Target number of participants achieved
- Co-PSMA data presented
- Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals